Barclays initiated coverage of Talkspace (TALK) with an Equal Weight rating and $3.50 price target The firm started the U.S healthcare technology and distribution industry with a neutral view. Barclays is most bullish on the drug distributors and has a more mixed view of the dental and healthcare information technology sub-sectors.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TALK:
- Talkspace management to meet with Northland
- Talkspace’s Growth Potential and Strategic Advancements Highlighted in Buy Rating by Ryan MacDonald
- Talkspace awarded renewal of Sourcewell cooperative purchasing contract
- Talkspace management to meet virtually with KeyBanc
- Talkspace Achieves Record Revenue Amid AI and Partnership Growth